Xibrom™(bromfenac ophthalmic solution) 0.09%

XIBROM™ophthalmic solution is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

Clinical studies in patients following cataract surgery demonstrated:

• Significant reduction of ocular inflammation and pain with twice-daily dosing¹

Comfort

• Minimal incidence of burning or stinging reported in clinical trials (1.4%)¹

Safety

• Few adverse events reported in clinical trials compared with placebo¹
• Lower preservative concentration (BAK) than currently available NSAIDs^2-4

Clinical practice experience:

• Used clinically in over 6 million patients in Japan¹

Xibrom in the News

• Donnenfeld Article 2007
• Review of Ophthalmology - November 2006

References:

1. Data on file. ISTA Pharmaceuticals, Inc.
2. Xibrom™ Prescribing Information.
3. Acular ® Prescribing Information.
4. Voltaren Ophtha™ Prescribing Information.

XIBROM™ ophthalmic solution is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.

The most commonly reported adverse experiences reported following use of XIBROM™ after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and iritis. These events were reported in 2-7% of patients